Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Equity Ratio (2020 - 2025)

Xeris Biopharma Holdings' Equity Ratio history spans 6 years, with the latest figure at 0.04 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 138.94% year-over-year to 0.04, compared with a TTM value of 0.04 through Dec 2025, up 138.94%, and an annual FY2025 reading of 0.04, up 138.94% over the prior year.
  • Equity Ratio for Q4 2025 was 0.04 at Xeris Biopharma Holdings, up from 0.0 in the prior quarter.
  • The five-year high for Equity Ratio was 0.31 in Q4 2021, with the low at 0.11 in Q1 2025.
  • Average Equity Ratio over 5 years is 0.05, with a median of 0.0 recorded in 2023.
  • Year-over-year, Equity Ratio soared 1068.8% in 2022 and then plummeted 848.05% in 2024.
  • Tracing XERS's Equity Ratio over 5 years: stood at 0.31 in 2021, then crashed by 58.08% to 0.13 in 2022, then plummeted by 116.03% to 0.02 in 2023, then tumbled by 336.05% to 0.09 in 2024, then surged by 138.94% to 0.04 in 2025.
  • Per Business Quant, the three most recent readings for XERS's Equity Ratio are 0.04 (Q4 2025), 0.0 (Q3 2025), and 0.06 (Q2 2025).